Beryl Drugs Profit & Loss Annual

BSE: 524606 | NSE: - | ISIN: INE415H01017 | Sector: Biotechnology & Drugs

19.95 -0.04 (-0.20%)Updated : 22 May 2025

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	26.73	26.89	14.60	14.09
Total Revenue	26.73	26.89	14.60	14.09
Costof Revenue Total	13.15	14.54	8.40	7.42
Gross Profit	13.58	12.35	6.20	6.67
Selling/ General/ Admin Expenses Total	1.93	1.70	1.31	1.18
Depreciation/ Amortization	1.19	0.80	1.07	1.25
Interest Exp( Inc) Net- Operating Total	0.01	0.01	0.02	0.02
Other Operating Expenses Total	9.38	8.71	4.48	4.05
Total Operating Expense	25.65	25.76	15.28	13.92
Operating Income	1.08	1.13	-0.68	0.17
Interest Inc( Exp) Net- Non- Op Total	-0.45	-0.42	-0.40	0.02
Gain( Loss)on Saleof Assets	0.01	-	-	-
Other Net	0.37	0.27	0.12	0.15
Net Income Before Taxes	1.01	0.98	-0.95	0.35
Provisionfor Income Taxes	0.24	0.22	-0.29	0.11
Net Income After Taxes	0.77	0.77	-0.66	0.24
Net Income Before Extra Items	0.77	0.77	-0.66	0.24
Net Income	0.77	0.77	-0.66	0.24
Income Availableto Com Excl Extra Ord	0.77	0.77	-0.66	0.24
Income Availableto Com Incl Extra Ord	0.77	0.77	-0.66	0.24
Diluted Net Income	0.77	0.77	-0.66	0.24
Diluted Weighted Average Shares	0.51	0.51	0.51	0.51
Diluted EPS Excluding Extra Ord Items	1.52	1.51	-1.30	0.47
Diluted Normalized EPS	1.50	1.51	-1.30	0.47
period Length	12.00	12.00	12.00	12.00
period Type	-	-	-	-
Total Adjustmentsto Net Income	-	0.00	-	-
Dilution Adjustment	-	0.00	-	-